AU2014220735B2 - Vortioxetine manufacturing process - Google Patents

Vortioxetine manufacturing process Download PDF

Info

Publication number
AU2014220735B2
AU2014220735B2 AU2014220735A AU2014220735A AU2014220735B2 AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2 AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2
Authority
AU
Australia
Prior art keywords
compound
formula
piperazine
process according
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014220735A
Other languages
English (en)
Other versions
AU2014220735A1 (en
Inventor
Kim Lasse Christensen
Thomas Ruhland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2014220735A1 publication Critical patent/AU2014220735A1/en
Application granted granted Critical
Publication of AU2014220735B2 publication Critical patent/AU2014220735B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2014220735A 2013-02-22 2014-02-20 Vortioxetine manufacturing process Active AU2014220735B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361767883P 2013-02-22 2013-02-22
DKPA201300104 2013-02-22
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (2)

Publication Number Publication Date
AU2014220735A1 AU2014220735A1 (en) 2015-08-20
AU2014220735B2 true AU2014220735B2 (en) 2017-06-22

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014220735A Active AU2014220735B2 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3915367A1 (en) 2010-08-18 2021-12-01 BioSplice Therapeutics, Inc. Diketones and hydroxyketones as catenin signaling pathway activators
PE20151721A1 (es) 2013-02-22 2015-12-07 Samumed Llc Y-dicetonas como activadores de la ruta de senalizacion de wnt/b-catenina
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
BR112017021277A2 (pt) * 2016-02-08 2018-06-26 H Lundbeck As Síntese de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina
MA45532A (fr) 2016-07-01 2019-05-08 H Lundbeck As Schémas posologiques de la vortioxétine destinés à une apparition rapide de l'effet antidépresseur
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
MY150647A (en) * 2006-06-16 2014-02-14 Lundbeck & Co As H 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
PL2958903T3 (pl) 2017-08-31
BR112015019268B1 (pt) 2023-01-10
AU2014220735A1 (en) 2015-08-20
IL240501A0 (en) 2015-09-24
CR20150423A (es) 2015-10-20
MA38338A1 (fr) 2016-09-30
AP2015008640A0 (en) 2015-08-31
IL240501B (en) 2018-08-30
GEP201706749B (en) 2017-10-10
ES2625380T3 (es) 2017-07-19
SMT201700238T1 (it) 2017-07-18
RS55932B1 (sr) 2017-09-29
SG11201506651SA (en) 2015-09-29
PH12015501807B1 (en) 2019-05-31
SI2958903T1 (sl) 2017-09-29
KR102230628B1 (ko) 2021-03-22
KR20150118146A (ko) 2015-10-21
CN104995181A (zh) 2015-10-21
MX2015010656A (es) 2015-12-17
MA38338B1 (fr) 2018-10-31
EP2958903B1 (en) 2017-04-12
JP6464098B2 (ja) 2019-02-06
ME02671B (me) 2017-06-20
MY172337A (en) 2019-11-21
DOP2015000187A (es) 2015-11-30
UA116236C2 (uk) 2018-02-26
JP2016509042A (ja) 2016-03-24
CY1118883T1 (el) 2018-01-10
LT2958903T (lt) 2017-08-25
HK1216098A1 (en) 2016-10-14
DK2958903T3 (en) 2017-05-15
MX362355B (es) 2019-01-14
PH12015501807A1 (en) 2015-11-09
CN104995181B (zh) 2017-03-08
RU2652265C2 (ru) 2018-04-27
RU2015134407A (ru) 2017-03-28
BR112015019268A2 (pt) 2020-01-28
US9353073B2 (en) 2016-05-31
HRP20170607T1 (hr) 2017-06-30
ZA201506050B (en) 2017-08-30
EA027756B1 (ru) 2017-08-31
TN2015000335A1 (en) 2017-01-03
PT2958903T (pt) 2017-05-26
EA201591349A1 (ru) 2015-12-30
CL2015002309A1 (es) 2016-03-04
PE20151589A1 (es) 2015-12-03
CA2901821A1 (en) 2014-08-28
US20160009670A1 (en) 2016-01-14
EP2958903A1 (en) 2015-12-30
WO2014128207A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
EP2958903B1 (en) Vortioxetine manufacturing process
JP6986045B2 (ja) キナーゼを修飾する1h−ピロロ[2,3−b]ピリジン誘導体の合成
JP6018644B2 (ja) 1−[2−(2,4−ジメチル−フェニルスルファニル)−フェニル]−ピペラジンの製造方法
JP6451652B2 (ja) (r)−1,1,3−トリメチル−4−アミノインダンの製造方法
Yin et al. Solvent-free copper-catalyzed N-arylation of amino alcohols and diamines with aryl halides
KR20220051168A (ko) 헤테로시클리덴아세트아미드 유도체의 제조 방법
CN105348220B (zh) 一种氢溴酸沃替西汀的合成方法
CN104628676A (zh) 一种Vortioxetine的制备方法
JP2014524438A (ja) インデノピリジン誘導体
HK1216098B (en) Vortioxetine manufacturing process
OA17454A (en) Vortioxetine manufacturing process.
US20180072690A1 (en) Methods for Making Serotonin Reuptake Inhibitors
CN107011288B (zh) 一种阿立哌唑中间体1-(2,3-二氯苯基)哌嗪盐酸盐的制备方法
NZ710779A (en) Vortioxetine manufacturing process
NZ710779B2 (en) Vortioxetine manufacturing process
JP2025083072A (ja) ボルチオキセチンの製造方法
JP5439745B2 (ja) ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
TW201825463A (zh) 用於製備1-(4-(2-((1-(3,4-二氟苯基)-1h-吡唑-3-基)甲氧基)乙基)哌-1-基)乙酮的方法和中間體
JP2011207844A (ja) ビベンゾイミダゾール化合物の製造方法
JP2022506577A (ja) D3ドーパミン受容体アゴニストを合成する方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ PA201300104 22 FEB 2013 DK

FGA Letters patent sealed or granted (standard patent)